Home › Funds › ADAR1 Capital Management, LLC › AGIO
ADAR1 Capital Management, LLC position in AGIO
AGIOS PHARMACEUTICALS INC · Health Care
ADAR1 Capital Management, LLC reported holding 1,288,053 shares of AGIO (AGIOS PHARMACEUTICALS INC) in its Q2 2026 13F filing — a position valued at US$47.8M, representing 2.65% of its reported portfolio and ranking #5 among its reported holdings. ADAR1 Capital Management, LLC has disclosed AGIO holdings in 7 of the last 8 reported quarters, going back to Q3 2024.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How ADAR1 Capital Management, LLC's AGIO position evolved
ADAR1 Capital Management, LLC first disclosed a stake in AGIO in Q3 2024 at 21,300 shares (US$946K). The position peaked in Q2 2026 at 1,288,053 shares, worth US$47.8M. Across 7 filings, ADAR1 Capital Management, LLC increased the stake 4 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 1,288,053 shares valued at US$47.8M — an increase of 1,147,381 shares quarter over quarter.. Notable position changes include a 29% increase in Q2 2025 (shares rose 21% over the following quarter), a 408% increase in Q4 2025 (shares rose 24% over the following quarter), a 816% increase in Q2 2026 (shares fell 10% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2024 | 21.30K | $946.36K | New |
| Q1 2025 | 27.90K | $817.47K | New |
| Q2 2025 | 35.90K | $1.19M | Add |
| Q3 2025 | 37.00K | $1.49M | Add |
| Q4 2025 | 188.00K | $5.12M | Add |
| Q1 2026 | 140.67K | $4.76M | Reduce |
| Q2 2026 | 1.29M | $47.80M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About AGIO and 13F data
AGIO (AGIOS PHARMACEUTICALS INC) is a Health Care company. 30 other funds we track also report a position in AGIO — the largest reported positions include Farallon Capital Management (US$219.6M), FARALLON CAPITAL MANAGEMENT, L.L.C. (US$219.6M), Lynx1 Capital Management LP (US$126.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding AGIO
- Farallon Capital Management 5.92M sh · $219.59M · Q2 2026
- FARALLON CAPITAL MANAGEMENT, L.L.C. 5.92M sh · $219.59M · Q2 2026
- Lynx1 Capital Management LP 3.41M sh · $126.51M · Q2 2026
- ARMISTICE CAPITAL, LLC 2.40M sh · $89.06M · Q2 2026
- Erste Asset Management GmbH 2.15M sh · $81.97M · Q2 2026
- Foresite Capital Management VI LLC 785.00K sh · $29.13M · Q2 2026
- Parkman Healthcare Partners LLC 669.05K sh · $24.83M · Q2 2026
More on ADAR1 Capital Management, LLC
FAQ
How long has ADAR1 Capital Management, LLC held AGIO?
ADAR1 Capital Management, LLC has disclosed AGIO holdings in 7 of the last 8 reported quarters, going back to Q3 2024.
What is ADAR1 Capital Management, LLC's current position in AGIO?
As of Q2 2026, ADAR1 Capital Management, LLC holds 1.29M shares of AGIO (AGIOS PHARMACEUTICALS INC), valued at $47.80M, representing 2.65% of its reported portfolio and ranking #5.
Has ADAR1 Capital Management, LLC been buying or selling AGIO?
In the latest 13F filing (Q2 2026), ADAR1 Capital Management, LLC increased its position in AGIO. The position peaked in Q2 2026 at 1.29M shares.
Which other funds hold AGIO?
Other major institutional holders of AGIO include Farallon Capital Management, FARALLON CAPITAL MANAGEMENT, L.L.C., Lynx1 Capital Management LP, among 30 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.